Product Description: Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C22H26O4
References: [1]Ashida, Y., et al., A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins, 1989. 38(1): p. 91-112./[2]Walsh, et al. Killian, AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. J Pharmacol Exp Ther, 1999. 290(1): p. 220-6./[3]Hao Y, et al. Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain Res. 2022 Nov 15;1795:148073.
CAS Number: 112665-43-7
Molecular Weight: 354.44
Compound Purity: 98.86
Research Area: Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Ferroptosis;JNK;MDM-2/p53;Prostaglandin Receptor;Reactive Oxygen Species
English
Deutsch
